Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Shreveport, La., Center Continues To Provide HIV/AIDS Services After 20 Years
The Shreveport Times profiled the 20-year-old Shreveport, La.-based Philadelphia Center, an agency that provides HIV/AIDS services to "an average of nearly 600 people each year in northwest Louisiana" and provides "about 1,400 free HIV tests each year." The organization also has a residential program called the Mercy Center, "a haven for homeless people with HIV or those fighting addiction and other challenges," according to the Times. The center in large part is supported by an annual auction from which proceeds "help the agency operate support groups, coordinate medical, dental and housing services for clients, provide food and medicine to people and offer free, on-the-spot HIV testing," the article states. The center recently opened a satellite office in a nearby town in response to an increase in HIV infections in the area (Brumble 8/2).
pharmacy online
International Society For Pharmaceutical Engineering Asks Pharma Professionals To Share Their Knowledge
ISPE, a global not-for-profit association of 25,000 pharmaceutical science and manufacturing professionals, announced that it is accepting proposals from pharmaceutical professionals for content that can be included in a variety of its educational res.
News of the day
HeartWorks Simulation - A Breakthrough In Education For Cardiothoracic Anesthesiologists
The world"s first virtual heart has been developed to improve teaching of peri-operative transesophageal echocardiography (TEE) skills in the care of patients with heart disease. HeartWorks, a uniquely realistic computer-generated model of the heart and echocardiography simulator, is the result of a 4 year project driven by a team of three London-based cardiac anaesthesiologists. Recognising the power of education through simulation and its increasingly widespread adoption throughout clinical practice, the team is spearheading a pathway change in education in one of the most interesting and challenging areas of cardiac care. Now in production by Inventive Medical, a subsidiary of UCLH Charity London, HeartWorks is set to dramatically transform TEE training by university teaching hospitals worldwide.
Diagnostics

Oramed Pharmaceuticals Reports Positive Results From A Study Of Oral Insulin Capsule On Type 1 Diabetic Patients

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed"s first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed"s trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients. Oramed"s oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion. Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed"s oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal." Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients. About Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed"s technology is based on over 25 years of research by top research scientists at Jerusalem"s Hadassah Medical Center. The Company"s corporate and R&D headquarters are based in Jerusalem. Forward-looking statements Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company"s ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company"s filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements. Oramed Pharmaceuticals Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009